# Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization

> **NCT03300401** · NA · WITHDRAWN · sponsor: **University of Southern California**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Perflutren Lipid Microspheres
- **DRUG:** Sulfur Hexafluoride Lipid Microspheres
- **DEVICE:** Dynamic Contrast-Enhanced Ultrasound Imaging
- **DEVICE:** Positron Emission Tomography
- **DEVICE:** Computed Tomography
- **BIOLOGICAL:** Yttrium-90 (90Y)

## Key facts

- **NCT ID:** NCT03300401
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-11-07
- **Primary completion:** 2019-11-07
- **Final completion:** 2020-11-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Accrual issue
- **Last updated:** 2019-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03300401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03300401, "Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03300401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*